Minimally invasive surgery (MIS) for spinal metastases — the percutaneous pedicle screw fixation, lateral access corpectomy, endoscopic decompression, and MIS stabilization approaches enabling spinal surgery in patients with limited performance status and expected survival — represent the surgical technology market expanding surgical candidacy for spinal metastasis, with the Metastases Spinal Tumor Market reflecting MIS as an important market development.

Traditional versus MIS spinal metastasis surgery — the conventional open posterior decompression and stabilization requiring significant muscle dissection and blood loss creating high morbidity in already-compromised cancer patients — limited surgical candidacy to patients with adequate performance status, life expectancy, and medically optimized status. MIS approaches reducing blood loss by sixty to eighty percent, cutting hospital stay by forty to fifty percent, and enabling faster return to chemotherapy creating the clinical rationale for expanded MIS adoption in oncology.

Percutaneous pedicle screw fixation for spinal metastasis — the fluoroscopically guided percutaneous screw placement providing spinal stabilization through small incisions without significant muscle dissection — enables spinal stabilization in patients who cannot tolerate open surgery. The combination of percutaneous stabilization with cement augmentation (vertebroplasty/kyphoplasty) creating the minimally invasive spinal metastasis stabilization approach that expanded surgical candidacy dramatically.

Minimally invasive lateral approaches — the XLIF (eXtreme Lateral Interbody Fusion), OLIF (Oblique Lateral Interbody Fusion), and lateral corpectomy enabling thoracolumbar metastasis resection without posterior instrumentation in appropriate cases — represent the lateral spine approach expansion to metastatic disease. NuVasive, Globus Medical, and Stryker competitive platform offerings for minimally invasive lateral spine surgery.

Do you think MIS approaches for spinal metastasis will eventually enable surgical treatment for most spinal metastasis patients regardless of performance status, or will biology and tumor burden continue limiting surgical candidacy?

FAQ

When is surgery indicated for spinal metastasis? Surgical indications: neurological deficit from cord compression (urgent decompression); spinal instability (Spinal Instability Neoplastic Score SINS ≥13); failed radiation; radioresistant tumor (renal cell, sarcoma); unknown primary requiring tissue diagnosis; life expectancy >three to six months; adequate performance status; Tomita score, Tokuhashi score, and SINS guide surgical decision-making; goals: neurological preservation/restoration, pain relief, stabilization, local control — not cure.

What is the SINS (Spinal Instability Neoplastic Score)? SINS assesses spinal instability from metastatic disease: location (junctional worse), pain (mechanical), lesion type (lytic worse), spinal alignment, vertebral body involvement, posterior element involvement; scores zero to eighteen; <7: stable (non-surgical); seven to twelve: indeterminate (surgical consultation); ≥13: unstable (surgical stabilization indicated); validated multidisciplinary assessment tool guiding surgical referral decisions; widely adopted in neuro-oncology and spine surgery practice.

#SpinalMetastasis #MISspine #MinimallyInvasiveSpine #SpineStabilization #SpinalOncologySurgery #PercutaneousSpine